UST OF PREFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO. APPLICATION NO. 8449-320-999 10/750,382						
APPLICANT Perez-Soler et al.						
FILING DATE December 30, 2003	GROUP 1614					

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBC	ZZAJS	FILING DATE IF APPROPRIATE
1412	A01	3,904,663	9/75	Tobe et al.				
V	A02	4,169,846	10/2/79	Kidani et al.				
	A03	4,200,583	4/29/80	Kidani et al.	1			
	A04	4,203,912	5/20/80	Hydes et al.	1			
	A05	4,230,631	10/28/80	Hydes et al.	1			
	A06	4,255,347	3/10/81	Kidani et al.				
	A07	4,256,652	3/17/81	Kidani et al.		Ι.		
	A08	4,431,666	2/14/84	Bulten et al.				
	A09	4,466,924	8/21/84	Verbeek et al.				
	A10	4,661,516	4/28/87	Brown et al.				
	All	4,758,588	7/19/88	Brown et al.				
	A12	4,760,155	7/26/88	Heffernan et al.				<u> </u>
	A13	4,760,157	7/26/88	Child et al.				
	A14	4,845,124	7/4/89	Kidani et al.				
	AI5	4,861,905	8/29/89	Nowatari et al.		$\perp \perp$		
	A16	4,946,954	8/7/90	Talebian et al.				
	A17	4,956,459	9/11/90	Talebian et al.		TT		
	A18	5,011,959	4/30/91	Khokhar et al.				·
	A19	5,041,578	8/20/91	Khokhar	I			
	A20	5,041,581	8/20/91	Khokhar et al.	T			
	A21	5,117,022	5/26/92	Khokhar et al.				
	A22	5,178,876	2/12/93	Khokhar et al.				
	A23	5,186,940	2/16/93	Khokhar et al.				
	A24	5,384,127	1/24/95	Perez-Soler et al.				
	A25	5,422,364	6/6/95	Nicolau				
	A26	5,843,475	12/1/98	Perez-Soler et al.				
	A27	6,613,799	9/2/03	Maeda et al.				
1 W	A28	6,696,079	2/24/04	Perez-Soler et al.			,	

	,		FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
							YES	NO
/ 从	BOI	EP 0113508	7/18/84	EP	_	_		
Mid	B02	EP 0130482	1/9/95	EP			<u></u>	<u>L</u>
	B03	EP 0136012	4/3/85	EP		<u> </u>		

Sheet 2 of 3

lux	B04	EP 0147926	7/10/85	EP	 		
- 00	B05	EP 0193936	5/6/89	EP			
	B06	EP 0237450	9/16/87	EP			
	B07	EP 0356332	2/28/90	EP			
	B08	WO 87/02364	4/23/87	PCT			
-	B09	WO 88/03925	6/2/88	PCT			
/^~	Bic	WO 90/02131	3/8/90	PCT			

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)				
/ Sh	C01	Connors, T.A. et al, "New Platinum Complexes with Anti-Tumor Activity"ChemBiol. Interactions, 5:415-424 (1972).				
	C02	Craciunescu, D.G. et al, "On the preparation, antitumour and cytotoxic evaluation of some new analogues of the cis-dichloro (1,2-diamino-cyclohexane) platinum (II) complex", Eur. J. Med. ChemChem. Ther., 19:353-357 (1984).				
	C03	Deliconstantinos, G. et al, "Incorporation of Cis-Dichlorobiscyclopentylamineplatinum (II) into Liposomes Enhances its Uptake by Adj/PC6A Tumours Implanted Subcutaneously into Mice", Abstract from Biochem. Soc. Trans., 5(5):1326-1328 (1977).				
	C04	Freise, J. et al, "Pharmacokinetics of Liposome Encapsulated Cisplatin in Rats", Archies Internationales de Pharmacodynamie et de Therapie, 258(2):180-192 (Aug. 1982).				
	C05	Han et al., 1996, "Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R,R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R,R-1,2-diaminocyclohexane-platinum (II)", Cancer Chemother. Pharmacol. 39:17-24.				
	C06	Han et al., Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res. 53:4913-19, 1993.				
	C07	Han et al., Intraliposomal conversion of lipophilic 1,2-DACH-bisalkyl-platinum(II) complexes into DACH-Pt-Cl.sub.2 (II). Proceed AACR 37:2740 p. 401, 1996.				
	C08	Han et al., Liposomal-platinum (II) compounds (L-Pt): optimization of formulation parameters. Proceed AACR 35:2482 p. 416., 1994.				
	C09	Hollis et al., cis-diamineplatinum (II) complexes containing phosphono carboxylate ligands as antitumor agents. J Med Chem. 33:105-11, 1990.				
	C10	Ismail et al., .sup.195 Pt- and .sup.15 N-NMR studies of antitumor complexes. ACS Symposium Series, 209:171-190, 1983.				
	CII	Kaledin, V. et al, "Intralymphatic Administration of Liposome-Encapsulated Drugs to Mice: Possibility for Suppression of the Growth of Tumor Metastases in the Lymph Nodes", Incl. 66(5):881-886 (May 1981).				
	C12	Khokhar et al., Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -S,S)-1,2-Diaminocyclohexane) Platinum(II) Complexs Incorporated in Liposomes. J. Med. Chem. 34:325-329, 1991.				
	C13	Khokhar et al., Toxicity and antitumor activity of cis-bis-carboxylato(trans-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes. Cancer Chemother Pharmacol. 23:219-24, 1989.				
	C14	Khokhar et al., Toxocity and efficacy studies on a series of lipid-soluble dineodecnoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes. Anticancer Drugs. 3:95-100, 1992.				
	C15	Khokhar, A.R. et al, "The Synthesis and Antitumor Properties of a Series of Water Soluble carboxylato-(1,2-diaminocyclohexane) Platinum(II) Complexes", Inorganica chimica Acta, 108(1):63-66 (Sep. 1985).				
	C16	Li et al., Improved antitumor activity of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) entrapped in long-circulating liposomes. Oncology Res. 7:611-17, 1995.				
	C17	Mori et al., In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol. 37:435-44, 1996.				
	C18	Perez-Soler et al., Clinical development of Liposomal Platinum. J Lip Res. 1:437-449, 1990.				
LSW	C19	Perez-Soler et al., Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecnoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. Cancer Res. 48:4509-12, 1988.				

Sheet 3 of 3

/cu	C20	Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res. 52:6341-47, 1992.
1	C21	Perez-Soler et al., Lipophilic cisplatin analogues entrapped in liposomes: role of chemical structure and liposome composition. Proceed AACR 32:2425 p.408, 1991
	C22	Perez-Soler et al., Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups. cancer Chemother Pharmacol. 33:378-84, 1994.
	C23	Perez-Soler et al., Lipophilic platinum compounds entrapped in liposomes: enhanced intraliposomal stability and preserved antitumor activity by using analogs with linear aliphatic leaving groups. Proceed AACR. 34:2182 p. 366, 1993.
	C24	Perez-Soler et al., Liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP): effect of lipid composition on biological activity. Proceed AACR. 31:2542 p. 428, 1990.
	C25	Perez-Soler, et al, "Phase I Clinical and Pharmacological Study of Liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane Platinum(II)", Cancer Research, 50(14):4254-4259 (Jul. 1990).
	C26	Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2,5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264., 1990
	C27	Qu et al., Effect of diamine linker on the chemistry of Bis(Platinum) complexes. A comparison of the Aqueous solution behavior of 1,4-butanediamine and 2.5-dimethyl-2,5-Hexanediamine Complexes. J. Inorganic Biochem. 40:255-264., 1990.
	C28	Qu et al., Interaction of bis(platinum) complexes with the mononucleotide 5'-guanosine monophosphate. Effect of diamine linker and the nature of the bis(platinum) complex of product formation. J. Am. Chem. Soc. 113:4851-4857, 1991.
	C29	Ridgway, H.J. et al, "Analogs of Sulfato 1,2-Diaminocyclohexane Platinum(II) I Modifications in Leaving Ligand", Wadley Medical Bulletin, 7(1):220,229 (1977).
	C30	Schwartz, P. et al, "Preparation and Antitumor Evaluation of Water-Soluble Derivatives of Dichloro(1,2-diaminocyclohexane)platinum(II)", Cancer Treatment Reports, 61(8):1519-1525 (Nov., 1977).
(C31	Slavin et al., Phosphonato complexes of platinum(II): kinetics of formation and phosphorus-31 NMR characterization studies. J Inorg Biochem. 40: 339-47, 1990.
	C32	Sur et al, "Effect of liposomal encapsulation of cis-platinum diaminodichloride in the treatment of Ehrlich ascites carcinoma", Oncology, 40(5):372-376 (1983).
C33 Vollano, J.F. et al, "Comparative Antitumor Studies on Platinum(II) and Pl		Vollano, J.F. et al, "Comparative Antitumor Studies on Platinum(II) and Platinum(IV) Cmplexes Containing 1,2-Diaminocyclohexane", J. Med. Chem., 30:716-719 (1987).
	C34	Yatvin, M.B. et al, "Selective Delivery by Hyperthermia of Liposome Encapsulated Cis Dichlorodiamine Platinum (II) and Tumor Growth Delay", Abstract from Proc. Am. Assoc. Cancer Res., 21:281 (1980).
100	(35	Yatvin, M.B. et al, "Selective Delivery of liposome-associated cis-dichlorodiamineplatinum (II) by heat and its influence on tumor drug uptake and growth", Cancer Research, 41(5):1602-1607 (May 1981).
1/ 1/ 1/		

EXAMINER	Kishu	DATE CONSIDERED	3/00
*EXAMINER: Initial is considered. Include con	f reference considered, whether or not citation by of this form with next communication to a	on is in conformance with MPEP 609; Draw line the applicant.	rough citation if not in conformance and not